Pulmonary disease in polymyositis/dermatomyositis.
D000293:Adolescent; D000328:Adult; D000368:Aged; D003520:Cyclophosphamide / Q000009:adverse effects; D003882:Dermatomyositis / Q000150:complications* / Q000188:drug therapy; D005260:Female; D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects; D008297:Male; D008727:Methotrexate / Q000009:adverse effects; D008875:Middle Aged; D009220:Myositis / Q000150:complications* / Q000188:drug therapy; D011015:Pneumonia, Aspiration / Q000175:diagnosis / Q000209:etiology* / Q000628:therapy; D011241:Prednisone / Q000627:therapeutic use; D011658:Pulmonary Fibrosis / Q000175:diagnosis / Q000188:drug therapy / Q000209:etiology*; D012131:Respiratory Insufficiency / Q000175:diagnosis / Q000209:etiology* / Q000628:therapy; D012189:Retrospective Studies
D007166:Immunosuppressive Agents; D003520:Cyclophosphamide; D011241:Prednisone; D008727:Methotrexate